BioWorld

March 23, 2009

Poniard's Pipeline Narrows to Picoplatin After Cost Cutting

Poniard Pharmaceuticals Inc. is cutting 12 percent of its staff and discontinuing in-house preclinical research operations, the latest in a recent spate of layoffs. (BioWorld Today) Read More

HHS, IOM Take First Steps on Comparative Effectiveness

'Endogenous Lithium' Found to Play Role in Schizophrenia

NewCo News: Otonomy Tackles Hearing and Balance Disorders with Delivery

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026